Chemometec A/S
Notification of managers' transactions
Notification of managers' transactions
ANNOUNCEMENT NO. 288
10 February 2025
Notification of managers’ transactions
ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.
See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document.
For further information, please contact:
Kim Nicolajsen, CFO
Telephone (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank11.2.2025 09:30:00 CET | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
Lån & Spar Bank A/S11.2.2025 08:29:42 CET | Pressemeddelelse
Indkaldelse til ordinær generalforsamling 2025
FirstFarms A/S11.2.2025 08:08:39 CET | Press release
Constantinsborg A/S has decided to submit a voluntary cash offer to FirstFarms A/S’ shareholders and will pursue a delisting of FirstFarms A/S
FirstFarms A/S11.2.2025 08:08:39 CET | Pressemeddelelse
Constantinsborg A/S har besluttet at fremsætte et frivilligt kontant købstilbud til aktionærerne i FirstFarms A/S og vil søge FirstFarms A/S afnoteret
ING Group11.2.2025 08:00:00 CET | Press release
Progress on share buyback programme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom